What are the recommended starting doses, titration schedule, contraindications, and common side effects of doxepin for insomnia and mood disorders?

Doxepin for Insomnia and Mood Disorders

Recommended Starting Doses and Titration

For insomnia, start doxepin at 3 mg taken 30 minutes before bedtime, and if sleep maintenance remains inadequate after 1–2 weeks, increase to 6 mg. 1, 2 These low hypnotic doses (3–6 mg) exploit selective H₁-histamine receptor antagonism while avoiding the anticholinergic, noradrenergic, and serotonergic effects seen at antidepressant doses (≥25 mg). 2

For mood disorders (depression/anxiety), the starting dose is 75 mg daily, which can be increased to 75–150 mg/day for mild-to-moderate illness or up to 300 mg/day in severely ill patients. 3 The antidepressant effect typically requires 2–3 weeks to manifest, whereas the anti-anxiety effect appears earlier. 3

Titration Schedule for Insomnia

• Week 0: Begin 3 mg at bedtime
• Week 1–2: Reassess sleep-onset latency, wake after sleep onset, total sleep time, and daytime functioning 1
• Week 2+: If 3 mg is well-tolerated but insufficient, increase to 6 mg 1, 2
• Do not exceed 6 mg for insomnia—higher doses increase anticholinergic burden without additional hypnotic benefit 2

Titration for Depression/Anxiety

• Start 75 mg daily (may divide or give once at bedtime if ≤150 mg) 3
• Adjust at appropriate intervals based on response 3
• Maximum 300 mg/day; doses above this rarely add benefit 3

Contraindications

Absolute contraindications:

• Concurrent use with or within 14 days of monoamine oxidase inhibitors (MAOIs) 3
• Acute recovery phase following myocardial infarction 3
• Glaucoma or urinary retention (due to anticholinergic effects at higher doses) 3

Relative contraindications and cautions:

• Elderly patients require lower starting doses and close monitoring for confusion and oversedation 3
• Hepatic or renal impairment necessitates cautious dose selection 3
• Cardiovascular disease (hypotension, hypertension, tachycardia, and QRS widening can occur) 3
• History of seizures (tricyclics lower seizure threshold) 3
• Bipolar disorder (may precipitate manic switch; use only with concurrent mood stabilizer) 3

Common Side Effects

At Low Hypnotic Doses (3–6 mg)

Low-dose doxepin has a safety profile comparable to placebo in controlled trials, with no significant difference in adverse event rates. 1, 4, 5 The most common side effects are:

• Headache (occurs in ~15% of patients, similar to placebo) 4
• Somnolence/sedation (mild, tends to resolve with continued use) 4, 5
• No anticholinergic effects (dry mouth, constipation, urinary retention) at hypnotic doses 1, 4, 5
• No next-day residual sedation or psychomotor impairment 4, 5
• No tolerance, rebound insomnia, or withdrawal symptoms in trials up to 3 months 1

At Antidepressant Doses (≥75 mg)

Higher doses produce dose-dependent anticholinergic and cardiovascular effects:

• Anticholinergic: Dry mouth, blurred vision, constipation, urinary retention 3
• CNS: Drowsiness (most common), confusion, disorientation, hallucinations, tremor, seizures 3
• Cardiovascular: Hypotension, hypertension, tachycardia, QRS widening (ECG monitoring required in overdose) 3
• Other: Weight gain, dizziness, tinnitus, sweating, sexual dysfunction 3

Withdrawal Considerations

Gradual tapering is required after prolonged use at antidepressant doses to avoid withdrawal symptoms (not indicative of addiction but can include rebound anxiety and insomnia). 3 Low-dose doxepin (3–6 mg) does not require tapering. 1

Position in Treatment Guidelines

For insomnia, doxepin 3–6 mg is a second-line pharmacologic option recommended by the American Academy of Sleep Medicine after first-line benzodiazepine receptor agonists (BzRAs) or ramelteon have failed or are contraindicated. 1 It is specifically indicated for sleep-maintenance insomnia (wake after sleep onset), reducing nocturnal awakenings by 22–23 minutes. 1, 4, 5

Cognitive Behavioral Therapy for Insomnia (CBT-I) must be initiated before or alongside doxepin, as pharmacotherapy should supplement—not replace—behavioral interventions. 1

For mood disorders, doxepin is positioned as a tricyclic antidepressant with both antidepressant and anxiolytic properties, though newer agents (SSRIs, SNRIs) are typically preferred first-line due to better tolerability. 6

Special Population Considerations

Elderly Patients

• Start at the low end of the dosing range (3 mg for insomnia, 25–50 mg for depression) 3
• Monitor closely for confusion, oversedation, falls, and anticholinergic effects 3
• Elderly patients are more likely to have decreased renal/hepatic function requiring dose adjustment 3

Comorbid Insomnia and Anxiety/Depression

Low-dose doxepin (12.5 mg/day) significantly improves both sleep quality and anxiety symptoms in patients with comorbid insomnia and anxiety disorders. 6 However, low-dose doxepin (<25 mg/day) does not improve sleep in patients with major depressive disorder, suggesting it should not be used as monotherapy for insomnia in actively depressed patients. 7

Common Pitfalls to Avoid

• Do not use doxepin >6 mg for insomnia—higher doses increase anticholinergic burden without added sleep benefit 2
• Do not prescribe doxepin for insomnia without concurrent CBT-I—behavioral therapy provides more durable long-term outcomes 1
• Do not abruptly discontinue antidepressant doses—taper gradually to avoid withdrawal symptoms 3
• Do not combine with MAOIs or use within 14 days of MAOI discontinuation—risk of hypertensive crisis 3
• Monitor elderly patients closely—they are at higher risk for confusion, falls, and anticholinergic toxicity 3